MRKR - Marker Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7300
+0.0500 (+1.87%)
As of 3:03PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.6800
Open2.7000
Bid2.7200 x 1800
Ask2.7400 x 1200
Day's Range2.6600 - 2.7600
52 Week Range2.6100 - 9.1700
Volume285,409
Avg. Volume297,338
Market Cap124.825M
Beta (3Y Monthly)0.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results

    Conference Call and Webcast Today at 5:00pm EST HOUSTON , Nov. 12, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development ...

  • PR Newswire

    Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019

    HOUSTON , Nov. 11, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs

    HOUSTON , Aug. 15, 2019   /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results

    HOUSTON , Aug. 8, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Appoints Steve Elms to its Board of Directors

    HOUSTON, Aug. 6, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Steve Elms to its Board of Directors, effective August 6. "We are pleased to welcome Steve to our Board of Directors," said Peter L. Hoang, President & CEO of Marker.

  • PR Newswire

    Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR

    SAN FRANCISCO, July 20, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced interim data from an ongoing investigator-sponsored clinical trial led by Baylor College of Medicine, evaluating the Company's MultiTAA T cell therapy in patients with pancreatic adenocarcinoma. The data were reviewed today in an oral presentation during a plenary session, as well as a poster presentation, at the American Association for Cancer Research's (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy conference held in San Francisco, California from July 19-22, 2019.

  • PR Newswire

    Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma

    HOUSTON, July 17, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it will host a conference call and webcast with a question-and-answer session on Monday, July 22, 2019 at 5:30 a.m. PDT/ 8:30 a.m. EDT to review data from an investigator-sponsored Phase 1/2 clinical trial with its MultiTAA therapy in patients with pancreatic adenocarcinoma. The data will also be reviewed in plenary and poster sessions on Saturday, July 20 at a cell therapy conference hosted by the American Association for Cancer Research (AACR) in San Francisco by Brandon G. Smaglo, M.D., FACP, Assistant Professor, Medical Director of Hematology/Oncology at the Baylor College of Medicine, Houston, Texas.

  • PR Newswire

    Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma

    Data selected for oral presentation during a plenary session at AACR's Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy Conference Company to ...

  • Marker Therapeutics to Present at Two Upcoming Investor Conferences
    PR Newswire

    Marker Therapeutics to Present at Two Upcoming Investor Conferences

    HOUSTON , May 21, 2019 /PRNewswire/ --  Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results

    --Company on track to submit IND for Phase 2 AML clinical trial in the third quarter, with first patient enrolled by year end-- --MultiTAA T cell therapies continue to generate positive clinical results ...

  • PR Newswire

    Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference

    HOUSTON , May 7, 2019 /PRNewswire/ -- Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Provides Business and Clinical Update

    HOUSTON, March 28, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a business and clinical update, as well as an overview of upcoming milestones for 2019. "Our MultiTAA T cell therapies have continued to generate positive and compelling clinical data across various indications in several ongoing investigator-sponsored clinical trials led by Baylor College of Medicine (BCM).

  • Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th
    PR Newswire

    Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th

    HOUSTON , March 18, 2019 /PRNewswire/ -- Marker Therapeutics, Inc.  (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

    HOUSTON, Feb. 25, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced updated data from four clinical trials using the Company's multi-antigen targeted T cell (MultiTAA) therapies. Among the highlights, were results from an ongoing study including patients with acute myeloid leukemia (AML), which were reviewed in an oral presentation by Dr. Premal Lulla, M.B.B.S., Assistant Professor of Medicine, Baylor College of Medicine. "We continue to be highly encouraged by the clinical results we've seen to date with our MultiTAA therapies.

  • Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award
    PR Newswire

    Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award

    HOUSTON, Feb. 21, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Dr. Helen E. Heslop, Company co-founder and a founding member of Marker's Scientific Advisory Board, has been recognized with the ASBMT Lifetime Achievement Award at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019. The ASBMT Lifetime Achievement Award is presented annually and recognizes an individual who has made continuing contributions to the field of blood and marrow transplantation.

  • Marker Therapeutics to Present at the CAR-TCR Summit Europe
    PR Newswire

    Marker Therapeutics to Present at the CAR-TCR Summit Europe

    HOUSTON , Feb. 20, 2019 /PRNewswire/ --   Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility

    HOUSTON, Feb. 15, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company, today announced that it has formally relocated its corporate headquarters from Jacksonville, Florida to Houston, Texas. The Company also announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC), an incubator located in the heart of the Texas Medical Center, to access a fully equipped laboratory to conduct research and development.

  • Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
    PR Newswire

    Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development

    HOUSTON, Feb. 7, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company's therapeutic product candidates.

  • Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference
    PR Newswire

    Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference

    HOUSTON , Feb. 6, 2019 /PRNewswire/ -- Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019
    PR Newswire

    Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019

    HOUSTON , Jan. 17, 2019 /PRNewswire/ --  Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
    PR Newswire

    The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

    HOUSTON , Jan. 15, 2019 /PRNewswire/ --  Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire

    Marker Therapeutics Provides Updates of its Lead Clinical Programs

    HOUSTON, Jan. 3, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a year-end update in five clinical trials using the Company's therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.

  • ACCESSWIRE

    These 4 Healthcare Stocks May Test December Highs

    CORAL GABLES, FL / ACCESSWIRE / December 31,2018 / This year has been a year which has seen significant market volatility, but the healthcare sector has managed to remain above the curve by constantly working to design and implement innovative approaches to medical care for patients suffering from a variety of serious illnesses. As experts and professionals in the field have worked on developing technologies to improvequality of care available for consumers, the healthcare industry, as a whole, has seen tremendous growth. Premier Health Group (PHGRF) (PHGI), Axsome Therapeutics Inc (AXSM), Marimed Inc (MRMD), and Marker Therapeutics Inc (MRKR) are 4 healthcare companies worth keeping tabs on as we head into the new year.

  • Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit
    PR Newswire

    Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit

    HOUSTON , Dec. 6, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will present a corporate ...

  • The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
    PR Newswire

    The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting

    --Three abstracts accepted, including oral presentation on multiple myeloma clinical data-- HOUSTON , Nov. 27, 2018 /PRNewswire/ --  Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology ...